Abstract: Methods of assaying for (i) a pterin by immunoassay employing a pterin as capture agent, (ii) neopterin by chemiluminescent microparticle immunoassay (CMIA) employing an anti-neopterin antibody (Ab) as capture agent, (iii) neopterin by an immunoassay (IA) employing an acridinium (Acr)-labeled anti-neopterin Ab as conjugate, and (iv) neopterin by an IA employing Acr-labeled neopterin as tracer; an Acr-labeled anti-neopterin Ab; a conjugate/complex comprising anti-neopterin Ab and a carrier scaffold; a conjugated pterin; a conjugate comprising an Acr-labeled pterin and a carrier scaffold; an immunogen comprising neopterin and a carrier protein; a conjugate comprising such an immunogen and an Acr compound; an immunogen comprising a carrier protein and a neopterin hapten; a conjugate comprising such an immunogen and an Acr compound; a kit for assaying a pterin comprising a pterin as a capture agent and instructions for IA; and a kit for assaying neopterin comprising an anti-neopterin Ab as a capture agent and ins

Abstract: The present disclosure relates to isolated antibodies that can be used in an assay to determine the concentration levels of myeloperoxidase (MPO) in a test sample. Additionally, the present disclosure also relates to the use of improved test sample handling methods in assays in order to preserve the original MPO levels in the test sample.

Abstract: The invention provides a method for determining concentration of myeloperoxidase (MPO) in a human blood sample comprising: (a) providing a human peripheral blood sample stored under MPO preservation conditions; and (b) determining concentration of MPO in a plasma sample derived from the human peripheral blood sample. In a preferred embodiment, the MPO preservation conditions used in the invention comprise storage of the human peripheral blood sample in a plasma collection tube containing a leukocyte MPO secretion inhibitor. In this embodiment, the leukocyte MPO secretion inhibitor is preferably ethylene diamine tetraacetic acid (EDTA). The assays used in the inventive methods can comprise any clinically useful assay for determining MPO plasma concentration, including sandwich and competitive immunoassays, clinical chemistry assays and enzymatic assays.

Abstract: A preferably parametrically defined calibration target pattern definable in real-world coordinates (Xi,Yi) is used to spatially calibrate a camera system acquiring images in pixel coordinates (xi,yi). The calibration target pattern is used to produce a unique 1:1 mapping enabling the camera system to accurately identify each point in the calibration target pattern point mapped to each pixel in the acquired image. Preferably the calibration target pattern is pre-distorted and includes at least two sinusoids that create a pattern of distorted wavefronts that when imaged by the camera system will appear substantially linearized. Since wavefront locations on the calibration target pattern were known, a mapping between those wavefronts and the substantially linearized wavefront pattern on the camera system captured image can be carried out. Demodulation of the captured image enables recovery of the continuous wave functions therein, using spectral analysis and iteration.

Abstract: The present invention relates to methods of determining anti-infectious agent IgG avidity, for example, human anti-cytomegalovirus and human anti-toxoplasma IgG avidity, using a competitive assay format.

Abstract: Apparatus for image processing a sequence of images containing a parallel-pipelined image processor comprised of image memories, a pyramid processing circuit, an arithmetic logic unit, a crossbar switch for video routing through the various components of the processor, signal processors to provide hardware programming through a global bus and also perform image processing operations. Images can be passed directly from the crossbar switch to internal static RAM of the signal processors through a first-in, first-out interface at full video rates.

Abstract: Iris recognition is achieved by (1) iris acquisition that permits a user to self-position his or her eye into an imager's field of view without the need for any physical contact, (2) spatially locating the data defining that portion of a digitized video image of the user's eye that defines solely the iris thereof without any initial spatial condition of the iris being provided, and (3) pattern matching the spatially located data defining the iris of the user's eye with stored data defining a model iris by employing normalized spatial correlation for first comparing, at each of a plurality of spatial scales, each of distinctive spatial characteristics of the respective irises that are spatially registered with one another to quantitatively determine, at each of the plurality of spatial scales, a goodness value of match at that spatial scale, and then judging whether or not the pattern which manifests solely the iris of the user's eye matches the digital data which manifests solely the model iris in accordance

Abstract: Delivery system for topical application comprising a highly viscous carrier containing dissolved or dispersed and microencapsulated topically-active agents providing immediate and sustained release of the topically-active agent to localized body sites.